Med. Pro Praxi 2007; 5: 195-199

Statíny - majú dominantné miesto v kardiovaskulárnej prevencii? Lipidy znižujúce a pleiotropné účinky statínov

doc. MUDr. Daniel Pella PhD, MUDr. Viola Vargová PhD, MUDr. Ján Fedačko, MUDr. Richard Raši PhD
Centrum preventívnej a športovej medicíny, Klinika preventívnej medicíny a telovýchovného lekárstva lekárskej fakulty UPJŠ a Fakultnej nemocnice L. Pasteura v Košiciach

Posledné dekády znamenali zásadný pokrok v pochopení vzťahu medzi lipidovými poruchami a prevenciou kardiovaskulárnych chorôb. Nové hypolipemiká a určenie nových terapeutických cieľov značne expandovali možnosti liečby. Statíny získali pozíciu základných a najefektívnejších liekov na zníženie hladín sérového cholesterolu a kardiovaskulárnych príhod tak u pacientov s koronárnou chorobou srdca, ako aj bez nej. Od objavu prvého statínu pred 30 rokmi sa stala táto skupina liekov základným pilierom hypolipemickej terapie. V posledných rokoch sa zistilo, že mnoho pozitívnych účinkov statínov nie je možné vysvetliť jednoducho len znížením aterogénnych lipidov. Boli tiež dokázané nelipidové účinky statínov nazývané pleiotropnými účinkami, ktoré by mohli byť zodpovedné za tento aditívny benefit. Najdôležitejšími spomedzi pozitívnych pleiotropných účinkov statínov sú protizápalové, antiproliferačné, antitrombotické vlastnosti a zlepšenie endotelovej dysfunkcie.

Keywords: statíny, kardiovaskulárna prevencia, pleiotropné účinky, inhibítory hydroxymetylglutaryl-Co A-reduktázy; ateroskleróza, farmakoterapia

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pella D, Vargová V, Fedačko J, Raši R. Statíny - majú dominantné miesto v kardiovaskulárnej prevencii? Lipidy znižujúce a pleiotropné účinky statínov. Med. praxi. 2007;4(5):195-199.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva, World Health Organization; 2002.
    2. American Heart Association. Statistical fact sheet-populations.International Disease Statistics.Dallas, Tex: American Heart Association; 2003.
    3. Endo A, Kuroda M, Tanarawa K. Competitive inhibition of 3-HMGCoA reductase by ML 236 A and ML 236 B. Febs Lett 1976; 72: 323-326. Go to original source... Go to PubMed...
    4. Roberts J R. Lipid lowering drugs in atherosclerosis. Am J Cardiol 1996; 89: 682.
    5. Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389.
    6. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-1009. Go to original source... Go to PubMed...
    7. The long term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Eng J Med 1998; 339: 1349-1357.
    8. West of Scotland coronary prevention group. West of Scotland coronary prevention study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 346: 1339-1342.
    9. Downs J R, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. N Eng J Med 1999; 339: 1615-1622. Go to original source...
    10. Pedersen T R, Olsson A G, Faergeman O, et al, for the Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97: 1453-1460. Go to original source... Go to PubMed...
    11. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428. Go to original source... Go to PubMed...
    12. Veillard N R, Mach F. Statins: the new aspirin? Cell Mol Life Sci 2002; 59: 1771-1786. Go to original source... Go to PubMed...
    13. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Eng J Med 2002; 346: 539-540. Go to original source... Go to PubMed...
    14. ACC/AHA/NHLBI Clinical Advisory on Statins: clinical advisory on the use and safety of statins. JACC 2002; 40: 567-572. Go to original source... Go to PubMed...
    15. Chong P, Seeger J, Franklin C. Clinically relevant differences between the statins: implications for the therapeutic selection. Am J Med 2001; 111: 390-400. Go to original source... Go to PubMed...
    16. Chiang CE, Pella D, Singh RB. Coenzyme Q10 and adverse effects of statins. J Nutritional and Environmental Med 2004; 14: 1-12. Go to original source...
    17. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13. Go to original source... Go to PubMed...
    18. Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis.Circulation. 2003;107: 2270-2273. Go to original source... Go to PubMed...
    19. McKenney JM, Jones PH, Adamczyk MA. For the STELLAR study group. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 557-566. Go to original source... Go to PubMed...
    20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423. Go to original source... Go to PubMed...
    21. Schuster H, Fox JC. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004; 5 1187-1200. Go to original source... Go to PubMed...
    22. Bevilacqua M, Guazzini B, Righini V, et al. Metabolic effects of fluvastatin extended release 80mg and atorvastatin 20mg in patients with type 2 diabetes mellitus nad low serum high-density lipoprotein cholesterol levels: a 4 months, prospective, open label, randomised, blinded-end point (Probe) trial. Curr Ther Res 2004; 65: 330-344. Go to original source... Go to PubMed...
    23. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26: 890-896. Go to original source... Go to PubMed...
    24. Davignon J. The pleiotropic effects of drugs affecting lipid metabolism. Atherosclerosis XI. Elsevier, Paris 1998: 63-77.
    25. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109 (suppl III): III-39-III-43. Go to original source... Go to PubMed...
    26. Schoenbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors. Statins as antiinflammatory agents? Circulation 2004; 109 (suppl II): II-18-I -26. Go to original source... Go to PubMed...
    27. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906. Go to original source... Go to PubMed...
    28. Gokce N, Keaney JF. jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-1572. Go to original source... Go to PubMed...
    29. Marchesi S, Lupattelli G, Schillaci G, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36: 617-621. Go to original source... Go to PubMed...
    30. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol 2000; 15: 409-415. Go to original source... Go to PubMed...
    31. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Eng J Med 2000; 343: 1139-1147. Go to original source... Go to PubMed...
    32. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndromes. N Eng J Med 2004; 350: 1495-1504. Go to original source... Go to PubMed...
    33. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-1197. Go to original source... Go to PubMed...
    34. Weissberg PL. Atherogenesis: current understanding of the causes of atheroma. Heart 2000; 83: 247-252. Go to original source... Go to PubMed...
    35. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003; 35: 398-403. Go to original source... Go to PubMed...
    36. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581. Go to original source... Go to PubMed...
    37. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-2060. Go to original source... Go to PubMed...
    38. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080. Go to original source... Go to PubMed...
    39. Nissen SE, Nicholls SJ, Sipahi I, et al. Effetc of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565. Go to original source... Go to PubMed...
    40. Kaski J C. Infection, endothelial dysfunction, and atherogenesis. Circulation 2003; 108: E171- E172. Go to original source... Go to PubMed...
    41. Callahan A S 3rd. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep 2003; 5: 33-37. Go to original source... Go to PubMed...
    42. Borghi C, Dormi A, Veronesi M, et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004; 148: 285-292. Go to original source... Go to PubMed...
    43. Levy Y. Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease. Isr Med Assoc J 2004; 6: 490-491. Go to PubMed...
    44. Chu B, Hatsukami TS, Pollisar NL, et al. Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging. Stroke 2004; 35: 2444-2448. Go to original source... Go to PubMed...
    45. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-933. Go to original source... Go to PubMed...
    46. Singh, RB, Rastogi SS, Mechírová V. Significance of coenzyme Q10 in statin intoxication. Intern J Cardiol 2004; 97(suppl 2): S18. Go to original source...
    47. Yusuf S, Two decades of progress in preventing vascular disease. Lancet 2002; 6: 2-3. Go to original source... Go to PubMed...
    48. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97 (suppl): 52C- 60C. Go to original source... Go to PubMed...
    49. Moosmann B, Behl C. Selenoprotein synthesis and side effects of statins. Lancet 2004; 363: 892-894. Go to original source... Go to PubMed...
    50. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Amer J Cardiol 2004; 94: 1306-1310. Go to original source... Go to PubMed...
    51. Kumar A, Kaur H, Kumar S, et al. Atorvastatin alone/in combination with coenzyme Q10 in 103 cases of heart failure due to ischemic cardiomyopathy. In: Abstract book from the Fourth Conference of the International Coenzyme Q10 Association, Los Angeles 2005: 54-56.
    52. Nash DB, Nash SA. Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am J Cardiol 2004; 94: 35F-39F. Go to original source... Go to PubMed...
    53. Doggrell SA. New targets and new drugs down under in 2004. Drug News Perspect 2005; 18: 149-160.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.